Advances in new anti-tuberculosis targets and related drugs

Journal of China Pharmaceutical University

Volumn 43, Issue 1, 2012, Pages 1-8

  Wang, Jing ^a   Zhang, Hui Bin ^a   Zhou, Jin Pei ^a   Li, Qing ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Advances; Anti tuberculosis; Drug resistance; Mycobacterium tuberculosis; Target

Indexed keywords

TUBERCULOSTATIC AGENT;

MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; TUBERCULOSIS;

EID: 84863296402     PISSN: 10005048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. World Health Organization. Tuberculosis MDR-TB & XDR-TB 2011 progress report[EB/OL]. (2011-03-23) [2011-11-25]. http:/www.who.int/tb/challenges/mdr/ factsheet-mdr-progress-march2011.pdf.
2. Wang TC, Zhou JP, Zhang HB. Advances in the research of antituberculosis drugs[J]. J China Pharm Univ, 2010,41(4):299-305.
3. Boshoff HIM, Barry CE. Tuberculosis-metabolism and respiration in the absence of growth[J]. Nat Rev Microbiol, 2005,3(1):7080.
4. Muñoz-Elías EJ, McKinney JD. Carbon metabolism of intracellular bacteria[J]. Cell Microbiol, 2006,8(1):10-22. (Pubitemid 43355517)
5. Muñoz-Elías EJ, McKinney JD. Mycobacterium tuberculosis isocitrate lyase 1 and 2 are jointly required for in vitro growth and virulence[J]. Nat Med, 2005,11(6):638-644. (Pubitemid 40868304)
6. Gould TA, Langemheen HVD, Muñoz-Elías EJ, et al. Dual role of isocitrate lyase 1 in the glyoxylate and methylcitrate cycles in Mycobacterium tuberculosis[J]. Mol Microbiol, 2006,61(4):940947.
7. Sriram D, Yogeeswari P, Senthilkumar P, et al. Novel pthalazinyl derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis isocitrate lyase enzyme[J]. Med Chem, 2009,5(5):422-433.
8. Parish T, Stoker NG. The common aromatic amino acid biosynthesis pathway is essential in Mycobacterium tuberculosis[J]. Mcrobiology, 2002,148(10):3069- 3077. (Pubitemid 35243706)
9. Segura-Cabrera A, Rodríguez-Pérez MA. Structure-based prediction of Mycobacterium tuberculosis shikimate kinase inhibitors by high-throughput virtual screening[J]. Bioorg Med Chem Lett, 2008,18(11):3152- 3157. (Pubitemid 351721011)
10. Kumar M, Verma S, Sharma S, et al. Structure-based in silico design of a high-affinity dipeptide inhibitor for novel protein drug target shikimate kinase of Mycobacterium tuberculosis[J]. Chem Biol Drug Des, 2010,76(3):277-284.
11. Reichau S, Jiao WT, Walker SR, et al. Potent inhibitors of a shikimate pathway enzyme from Mycobacterium tuberculosis: combining mechnism-and modeling-based design[J]. J Biol Chem, 2011,286(18):16197-16207.
12. Kumar K, Awasthi D, Berger WT, et al. Discovery of anti-TB agents that target the cell-division protein FtsZ[J]. Future Med Chem, 2010,2(8):1305-1323.
13. White EL, Suling WJ, Ross LJ, et al. 2-Alkoxycarbonylaminopyridines: inhibitors of Mycobacterium tuberculosis FtsZ[J]. J Antimicrob Chemother, 2002,50(1):111-114. (Pubitemid 34785263)
14. Jaiswal R, Beuria TK, Mohan R, et al. Totarol inhibits bacterial cytokinesis by perturbing the assembly dynamics of FtsZ[J]. Biochemistry, 2007,46(14):4211-4220. (Pubitemid 46559388)
15. Kumar K, Awasthi D, Lee SY, et al. Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents[J]. J Med Chem, 2011,54(1):374-381.
16. Sutherland AG, Alvarez J, Ding WD, et al. Structure-based design of carboxybiphenylindole inhibitors of the ZipA-FtsZ interaction[J]. Org Biomol Chem, 2003,1(23):4138-4140.
17. Breukink E, Kruijff DD. Upid II as a target for antibiotics[J]. Nat Rev Drug Discovery, 2006,5(4):321-323.
18. Eoh H, Brennan PJ, Crick DC. The Mycobacterium tuberculosis MEP (2C-methyl-D-erythritol 4-phosphate) pathway as a new drug target[J]. Tuberculosis 2009,89(1):1-11.
19. Obiol-Pardo C, Rubio-Martinez J, Imperial S. The methylerythritol phosphate (MEP) pathway for isoprenoid biosynthesis as a target for the development of new drugs against tuberculosis[J]. Curr Med Chem, 2011,18(9):1325-1338.
20. Singh N, Chevé G, Avery MA, et al. Targeting the methylerythritol phosphate (MEP) pathway for novel antimalarial, antibacterial and herbicidal drug discovery: inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) enzyme[J]. Curr Pharm Des, 2007,13(11):1161-1177. (Pubitemid 46744822)
21. Haemers T, Wiesner J, Poecke SV, et al. Synthesis of alpha-substituted fosmidomycin analogues as highly potent Plasmodium falciparum growth inhibitors[J]. Bioorg Med Chem Lett, 2006,16(7):1888-1891. (Pubitemid 43267371)
22. Mao JL, Eohc H, He R, et al. Structure activity relationships of compounds targeting Mycobacterium tuberculosis 1-deoxy-D-xylulose 5-phosphate syndiase[J]. Bioorg Med Chem Lett, 2008,18(19):5320-5323.
23. Crane CM, Hirsch AKH, Alphey MS, et al. Synthesis and characterization of cytidine derivatives that inhibit the kinase IspE of the non-mevalonate pathway for isoprenoid biosynthesis[J]. ChemMedChem, 2008,3(1):91-101.
24. Geist JG, Lauw S, Illarionova V, et al. Thiazolopyrimidine inhibitors of 2-methylerythritol 2,4-cyclodiphosphate synthase (IspF) from Mycobacterium tuberculosis and Plasmodium falciparum[J]. ChemMedChem, 2010,5(7):1092-1101.
25. Dhiman RK, Mahapatra S, Slayden RA, et al. Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential growth and recovery from non-replicating persistence[J]. Mol Microbiol, 2009,72(1):85-97.
26. Kurosu M, Crick DC. MenA is a promising drug target for developing novel lead molecules to combat Mycobacterium tuberculosis[J]. Med Chem, 2009,5(2):197-207.
27. Li XK, Liu NN, Zhang HN, et al. Synthesis and SAR studies of 1, 4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis[J]. Bioorg Med Chem Lett, 2010,20(21):6306-6309.
28. White EL, Southworth K, Ross L, et al. A novel inhibitor of Mycobacterium tuberculosis pantothenate synthetase[J]. J Biomol Screening, 2007,12(1):100-105. (Pubitemid 46224924)
29. Yang YH, Liu YS, Ji XY, et al. A discovery of novel Mycobacterium tuberculosis pantothenate synthetase inhibitors based on the molecular mechanism of actinomycin D inhibition[J]. Bioorg Med Chem Lett, 2011,21(13):3943-3946.
30. Schaible UE, Kaufmann SHE. Iron and microbial infection[J]. Nat Rev Microbiol, 2004,2(12):946-953. (Pubitemid 39562533)
31. Monfeli RR, Beeson C. Targeting iron acquisition by Mycobacterium tuberculosis[J]. Infect Disord: Drug Targets, 2007,7(3):213-220. (Pubitemid 350028054)
32. Qiao CH, Gupte A, Boshoff HI, et al. 5′-O-[(N-Acyl)sulfamoyl] adenosines as antitubercular agents that inhibit MbtA: an adenylation enzyme required for siderophore biosynthesis of the Mycobactins[J]. J Med Chem, 2007,50(24):6080-6094.
33. Neres J, Labello NP, Somu RV, et al. Inhibition of siderophore biosynthesis by 2-triazole substituted analogues of 5′-O-[N--(Salicyl) sulfamoyl] adenosine: antibacterial nucleosides effective against Mycobacterium tuberculosis [J]. J Med Chem, 2008,51(23):7495-7507.
34. Bialy L, Waldmann H. Inhibitors of protein tyrosine phosphatases: next-generation drugs[J]. Angew Chem: Int Ed, 2005,44(25):3814-3839. (Pubitemid 40885689)
35. Bach H, Papavinasasundaram KG, Wong D, et al. Mycobacterium tuberculosis virulence is mediated by PtpA dephosphorylation of human vacuolar protein sorting 33 B[J]. Cell Host Microbe, 2008,3(5):316-322. (Pubitemid 351635998)
36. He YT, Zhang X, Xu J, et al. Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents[J]. PNAS, 2010,107(10):4573-4578.
37. Michael M, Michael S, Heino PPD, et al. Discovery of Mycobacterium tuberculosis protein tyrosine phosphatase A (MptpA) inhibitors based on natural products and a fragment-based approach[J]. Chem Bio Chem, 2005,6(10):1749-1753.
38. Chiaradia LD, Mascarello A, Purificaao M, et al. Synthetic chalcones as efficient inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase PtpA[J]. Bioorg Med Chem Lett, 2008,18(23):6227-6230.
39. Rawls KA, Lang PT, Takeuch J, et al. Fragment-based discovery of selective inhibitors of the Mycobacterium tuberculosis protein tyrosine phosphatase PtpA[J]. Bioorg Med Chem Lett, 2009,19(24):6851-6854.
40. Chandra K, Dutta D, Das AK, et al. Design, synthesis and inhibition activity of novel cyclic peptides against protein tyrosine phosphatase A from Mycobacterium tuberculosis[J]. Bioorg Med Chem, 2010,18(23):8365-8373.
41. Silva AP, Tabernero L. New strategies in fighting TB: targeting Mycobacterium tuberculosis-secreted phosphatases MptpA & MptpB[J]. Future Med Chem, 2010,2(8):1325-1337.
42. Weide T, Arve L, Prinz H, et al. 3-Substituted indolizine-1-carbonitrile derivatives as phosphatase inhibitors[J]. Bioorg Med Chem Lett, 2006,16(1):59-63. (Pubitemid 41625641)
43. Nören-Müller A, Wilk W, Saxena K, et al. Discovery of a new class of inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B by biology-oriented synthesis[J]. Angew Chem: Int Ed, 2008,47(32):5973-5977.
44. Tan LP, Wu H, Yang PY, et al. High-throughput discovery of Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) inhibitors using click chemistry[J]. Org Lett, 2009,11(22):5102-5105.
45. Pohlmann J, Lampe T, Shimada M, et al. Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action[J]. Bioorg Med Chem Lett, 2005,15(4):1189-1192. (Pubitemid 40458671)
46. Clifton EB, Richard EL, Khisimusi M, el al. Mycotic acids: structure, biosynthesis and physiological functions[J]. Prog Lipid Res, 1998,37(2/3):143-179.
47. Bhave DP, Muse WB, Carroll KS. Drug targets in Mycobacterial sulfur metabolism[J]. Infect Disord: Drug Targets, 2007,7(2):140-158. (Pubitemid 47099125)
48. Buchmeier NA, Newton GL, Koledin T, et al. Association of mycothiol with protection of Mycobacterium tuberculosis from toxic oxidants and antibiotics[J]. Mol Microbiol, 2003,47(6):17231732.
49. David WG, Daniel JS, Vuyo M, et al. Conjugates of plumbagin and phenyl-2-amino-1-thioglucoside inhibit MshB, a deacetylase involved in the biosynthesis of mycothiol[J]. Bioorg Med Chem, 2010,18(7):2501-2514.
50. Gerald LN, Nancy B, James JLC, et al. Evaluation of NTF1836 as an inhibitor of the mycothiol biosynthetic enzyme MshC in growing and non-replicating Mycobacterium tuberculosis[J]. Bioorg Med Chem, 2011,19(13):3956-3964.
51. Metaferia BB, Ray S, Smith JA, et al. Design and synthesis of substrate-mimic inhibitors of mycothiol-s-conjugate amidase from Mycobacterium tuberculosis[J]. Bioorg Med Chem Lett, 2007,17(2):444-447. (Pubitemid 46073749)
52. McLean KJ, Dunford AJ, Neel R, el al. Structure, function and drug targeting in Mycobacterium tuberculosis cytochrome P450 systems[J]. Arch Biochem Biophys, 2007,464(2):228-240. (Pubitemid 47210919)
53. Gao Q, Kripke KE, Saldanha AJ, et al. Gene expression diversity among Mycobacterium tuberculosis clinical isolates[J]. Microbiology, 2005,151(1):5-14. (Pubitemid 40207664)
54. McLean KJ, Carroll P, Lewis DG, et al. Characterization of active site structure in CYP121[J]. J Biol Chem, 2008,283(48):33406-33416.
55. Pandey AK, Sassetti CM. Mycobacterial persistence requires the utilization of host cholesterol[J]. PNAS, 2008,105(11):43764380.
56. Schnappinger D, Ehrt S, Voskuil MI, et al. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages, insights into the phagosomal environment[J]. J Exp Med, 2003,198(5):693-704. (Pubitemid 37087769)
57. Driscoll MD, McLean KJ, Cheesman MR, et al. Expression and characterization of Mycobacterium tubercuhsis CYP144: common themes and lessons learned in the M. tuberculosis P450 enzyme family[J]. Biochim Biophys Acta, 2011,1814(1):76-87.
58. Ouellet H, Kells PM, Montellano PRO, et al. Reverse type I inhibitor of Mycobacterium tuberculosis CYP125A1[J]. Bioorg Med Chem Lett, 2011,21(1):332-337.